Content area
Full Text
Letters to the Editor
970 complexity of AML,14 this is a step forward to an easier and highly efcacious GEP-driven therapeutic strategy.15
CONFLICT OF INTEREST
The authors declare no conict of interest.
ACKNOWLEDGEMENTS
Celgene provided lenalidomide free of charge. This study was supported in part by AIL Pesaro Onlus, AIRC (5xMille 10007 and IG10519) and FIRB Futura 2011.
AUTHORS CONTRIBUTIONSGV, FF and AI designed the research and wrote the manuscript; FDR, MRC, CR and GS treated the patients, collected the data and commented on the manuscript; FL and AV collected and analyzed the data and commented on the manuscript; PPP and MR performed the statistical analysis. AG, MR, and MAL generated GEP; FF performed GEP data analysis; SP performed EBM diagnostic accuracy analysis; PPP, SAP, AI and GV designed the molecular analysis and funded it, analyzed GEP data and wrote the manuscript.
G Visani1, F Ferrara2, F Di Raimondo3, F Loscocco1, G Sparaventi1, S Paolini4, F Fuligni4, A Gazzola4, M Rossi4, MA Laginestra4,
MR Caraci3, C Riccardi2, M Rocchi5, A Visani4, SA Pileri4, PP Piccaluga4,6 and A Isidori1,6
1Hematology and Hematopoietic Stem Cell Transplant Center, AORMN, Pesaro, Italy;
2Hematology, Cardarelli Hospital, Napoli, Italy;
3Hematology, Catania University, Catania, Italy;
4Hematopathology Section, Department of Experimental, Diagnostic, and Specialty Medicine, S. Orsola-Malpighi Hospital, Bologna
University School of Medicine, Bologna, Italy and
5Institute of Biomathematics, Urbino University, Urbino, Italy E-mail: [email protected]
6These authors contributed equally to this work.
REFERENCES
1 Estey EH. How to manage high-risk acute myeloid leukemia. Leukemia 2012; 26:
861869.2 Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 2010; 28: 49194925.
3 Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN et al. A phase II study of high dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011; 117: 18281833.
4 Pollyea DA, Kohrt HE, Gallegos L, Figueroa ME, Abdel-Wahab O, Zhang B et al.
Safety, efcacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2012; 26: 893901.
5 Pollyea DA, Zehnder J, Coutre S, Gotlib JR, Gallegos L, Abdel-Wahab O et al.
Sequential azacitidine plus lenalidomide combination for...